BioSpace News Archive

SMSbiotech, Inc. announced that a recent study on the interaction between Alveolar Type 2 cells and Small Mobile Stem cells demonstrates critical changes to the gene expression of the AT2 cells responsible for regenerating lung cells.

The Accu-Joint is indicated for use in the treatment of patients with degenerative and post-traumatic arthritis in the MTP joint in the presence of good bone stock, along with the following clinical conditions: Hallux Limitus, Hallux Rigidus, and an unstable or painful MTP joint

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac resynchronization therapy (CRT) for patients with mild heart failure (HF).

Each option is exercisable into one common share at a price of $0.25 per share and will vest immediately. The options will expire two years from the date of grant.

Anuncia Inc., an emerging leader in Cerebral Spinal Fluid (CSF) management, received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its ReFlow ™ System Mini intended for the treatment of CSF disorders requiring shunting

ProPharma Group, a portfolio company of Odyssey Investment Partners, announces the acquisition of Diamond Pharma Services. Diamond Pharma Services provides regulatory affairs, pharmacovigilance, and compliance & quality services to support pharmaceutical and biotechnology companies in obtaining and maintaining medicinal product licenses throughout all stages of a product’s life cycle.

Healing Innovations, Inc., announced the successful completion of the first pilot for the new Rise&Walk™ InClinic technology at Shepherd Center in Atlanta, Georgia, USA.

Epizyme’s Next EPIsode: Vision for Rewriting Oncology Treatment with Epigenetics Showcased New Five-Year Corporate Strategy

Gulf FZ LCC, subsidiary of Cipla Limited referred to as “Cipla” and biopharmaceutical company Alvotech announced that they are expanding their partnership for the marketing and distribution of four biosimilar medicines in Australia and New Zealand.

Bioelectronica Corporation announced the addition of new members to their team in Reno, NV, as the company continues to experience growing interest in their drug discovery platform, Hypercell®.